Galeterone (TOK-001 or VN/124-1) is a novel antiandrogen under development by Tokai Pharmaceuticals for the treatment of prostate cancer. It possesses a unique dual mechanism of action, acting as both anandrogen receptor antagonist and an inhibitor of CYP17A1, an enzyme required for the biosynthesis of theandrogens.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | Cytochrome P450
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye